| 15.9 0 (-4.96%) | 04-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 19.48 | 1-year : | 20.18 |
| Resists | First : | 16.68 | Second : | 17.28 |
| Pivot price | 16.3 |
|||
| Supports | First : | 15.71 | Second : | 13.07 |
| MAs | MA(5) : | 15.89 | MA(20) : | 16.4 |
| MA(100) : | 16.95 |
MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 12 | D(3) : | 12 |
| RSI | RSI(14): 33.2 | |||
| 52-week | High : | 17.9 | Low : | 13.17 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SWKH ] has closed above bottom band by 29.9%. Bollinger Bands are 144.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 15.94 - 16.02 | 16.02 - 16.08 |
| Low: | 15.68 - 15.79 | 15.79 - 15.88 |
| Close: | 15.75 - 15.91 | 15.91 - 16.05 |
SWK Holdings Corporation (SWKH) operates as a specialized financial institution, primarily concentrating its efforts within the healthcare sector. The company's operations are distinctly divided into two core segments: Finance Receivables and Pharmaceutical Development. Within its finance division, SWK offers bespoke funding solutions tailored to a diverse array of life science enterprises. These include companies spanning biotechnology, medical devices, diagnostic tools, animal health, and pharmaceuticals, alongside various institutions and individual innovators. Furthermore, the company extends non-discretionary investment advisory services, managing separate accounts for institutional clients keen on investing in the life science finance domain. Its Pharmaceutical Development segment involves the creation, formulation, production, and licensing of pharmaceutical products, leveraging its proprietary Peptelligence platform. A key strategic objective here is to license its internally developed product pipeline to external partners, aiming to generate innovative formulations through its unique technology, ultimately designed to benefit patients and their caregivers. Founded in 1996, the company underwent a name change from Kana Software, Inc. to SWK Holdings Corporation in December 2009. Its corporate headquarters are situated in Dallas, Texas.
Mon, 06 Apr 2026
SWK Holdings Tightens Covenants on 9% 2027 Notes After RWAY Deal, Adds Default Triggers - TradingView
Mon, 06 Apr 2026
SWK Holdings completes merger with Runway Growth Finance, delists from Nasdaq - Investing.com
Fri, 20 Mar 2026
SHAREHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders to Act Before the Vote--SWKH, COUR, JHG, and EHAB - PR Newswire
Mon, 06 Jan 2025
SWK Holdings Provides Portfolio Update - Yahoo Finance
Tue, 03 Oct 2023
Michael S Fields Net Worth (2026) - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 12 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 86.9 (%) |
| Shares Short | 69 (K) |
| Shares Short P.Month | 95 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.44 |
| Profit Margin | -6.8 % |
| Operating Margin | 19.3 % |
| Return on Assets (ttm) | -0.9 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | -27.8 % |
| Gross Profit (p.s.) | 2.97 |
| Sales Per Share | 3.1 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 27 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -75.72 |
| PEG Ratio | 0 |
| Price to Book value | 0.81 |
| Price to Sales | 5.11 |
| Price to Cash Flow | 7.04 |
| Dividend | 4 |
| Forward Dividend | 0 |
| Dividend Yield | 25.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|